-+ 0.00%
-+ 0.00%
-+ 0.00%
Faeth Therapeutics Partners With Roche on Phase 1b/2 Trial of PIKTOR Combination in Advanced Breast Cancer
Share
Listen to the news
Faeth Therapeutics Partners With Roche on Phase 1b/2 Trial of PIKTOR Combination in Advanced Breast Cancer
  • Faeth Therapeutics entered a clinical trial collaboration with Roche to evaluate PIKTOR in combination with investigational breast cancer drug giredestrant.
  • The planned Phase 1b/2 study will evaluate the combination in patients with hormone receptor-positive, HER2-negative advanced breast cancer.
  • PIKTOR is an investigational all-oral combination of serabelisib and sapanisertib targeting a pathway associated with resistance to endocrine therapy.
  • Faeth will sponsor and conduct the trial while retaining all PIKTOR rights. Roche will supply giredestrant.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faeth Therapeutics Inc published the original content used to generate this news brief via Business Wire (Ref. ID: 202611160700BIZWIRE_USPR_____20261116_BW192980) on November 16, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending